# Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)

> **NCT04278222** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Gastric Cancer
- Immunotherapy
- Anlotinib
- Toripalimab

## Interventions

- **DRUG:** Anlotinib Plus Toripalimab

## Key facts

- **NCT ID:** NCT04278222
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-10
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04278222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04278222, "Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04278222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*